PCSA officer receives 193 vested restricted shares

Q: What insider transaction did PCSA officer Patrick Lin report?

Patrick Lin reported acquiring 193 shares of Processa Pharmaceuticals Common Stock on January 1, 2026, at an exercise price of $0. The filing describes this as a distribution of vested restricted shares, reflecting equity compensation vesting rather than an open-market purchase or sale.

Q: How many Processa Pharmaceuticals shares are held through the Lin Family Trust?

The Form 4 shows 1,740 shares of Common Stock held indirectly through the Lin Family Trust Feb 4, 2024. This indirect holding is reported separately from Patrick Lin’s 1,753 directly owned shares, clarifying the structure of his beneficial ownership in PCSA.

Q: What role does Patrick Lin hold at Processa Pharmaceuticals (PCSA)?

Patrick Lin is identified as an officer of Processa Pharmaceuticals, serving as Chief Business - Strategy Officer. The Form 4 clarifies his relationship to the issuer, indicating he is not a director or 10% owner but a key executive officer.

Processa Pharmaceuticals Chief Business - Strategy Officer Patrick Lin reported a small equity transaction.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Processa Pharmaceuticals Chief Business - Strategy Officer Patrick Lin reported a small equity transaction. On January 1, 2026, Lin acquired 193 shares of Common Stock at an exercise price of $0 through the conversion of a derivative security, described as a distribution of vested restricted shares.

Following this vesting-related transaction, Lin directly beneficially owned 1,753 shares of Common Stock. In addition, 1,740 shares were held indirectly through the Lin Family Trust Feb 4, 2024, reflecting his combined direct and indirect ownership position in Processa Pharmaceuticals.

Insider Trade Summary

193 shares exercised/converted

Exercise 3 txns

Insider Lin Patrick

Role Chief Business - Strategy Off

Type	Security	Shares	Price	Value
Exercise	Common Stock	193	$0.00	$0.00
Exercise	Common Stock	193	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 contracts (Direct); Common Stock — 1,753 shares (Direct); Common Stock — 1,740 shares (Indirect, Lin Family Trust Feb 4, 2024)

Footnotes (1)

F1. Distribution of vested restricted shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PCSA officer Patrick Lin report?

Patrick Lin reported acquiring 193 shares of Processa Pharmaceuticals Common Stock on January 1, 2026, at an exercise price of $0. The filing describes this as a distribution of vested restricted shares, reflecting equity compensation vesting rather than an open-market purchase or sale.

How many PCSA shares does Patrick Lin own after this Form 4?

After the reported transaction, Patrick Lin directly beneficially owned 1,753 shares of Processa Pharmaceuticals Common Stock. The filing also shows an additional 1,740 shares held indirectly through the Lin Family Trust Feb 4, 2024, indicating both direct and trust-based holdings.

What does the transaction code M mean in the PCSA Form 4?

Transaction code M indicates an exercise or conversion of a derivative security into Common Stock. In this case, 193 derivative-linked shares converted at an exercise price of $0, which the filing explains as a distribution of vested restricted shares to the reporting person.

How many Processa Pharmaceuticals shares are held through the Lin Family Trust?

The Form 4 shows 1,740 shares of Common Stock held indirectly through the Lin Family Trust Feb 4, 2024. This indirect holding is reported separately from Patrick Lin’s 1,753 directly owned shares, clarifying the structure of his beneficial ownership in PCSA.

Was cash paid for the vested PCSA restricted shares?

No cash was paid for the vested shares according to the filing. The 193 Common Stock shares were acquired at an exercise price of $0, with the explanatory footnote stating this was a distribution of vested restricted shares as part of equity compensation.

What role does Patrick Lin hold at Processa Pharmaceuticals (PCSA)?

Patrick Lin is identified as an officer of Processa Pharmaceuticals, serving as Chief Business - Strategy Officer. The Form 4 clarifies his relationship to the issuer, indicating he is not a director or 10% owner but a key executive officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/04/2026 - 05:07 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Patrick

(Last)

(First)

(Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH

32960

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Business - Strategy Off

3. Date of Earliest Transaction (Month/Day/Year)
01/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/01/2026		M		193	A	$0⁽¹⁾	1,753	D
Common Stock								1,740	I	Lin Family Trust Feb 4, 2024

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	$0	01/01/2026		M			193	⁽¹⁾	⁽¹⁾	Common Stock	193	$0	0	D

Explanation of Responses:

1. Distribution of vested restricted shares.

	/s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR